References
- Hauschild A, Grob J, Demidov L, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. The Lancet. 2012;380:358–365.
- Hecht M, Zimmer L, Loquai C, et al. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Ann Oncol. 2015;26:1238–1244.
- Satzger I, Degen A, Asper H, et al. Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol. 2013;31:e220–e222.
- Conen K, Mosna-Firlejczyk K, Rochlitz C, et al. Vemurafenib-induced radiation recall dermatitis: case report and review of the literature. Dermatology. 2015;230:1–4.
- Alterio D, Marvaso G, Ferrari A, et al. Combination of dabrafenib and radiotherapy: could skin toxicity be affected by different irradiation techniques? BJR Case Rep. 2016;2:20150493.
- Anker CJ, Grossmann KF, Atkins BA, et al. Avoiding severe toxicity form combined BRAF inhibitor and radiation treamtent: consensus guidelines form the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys. 2016;95:632–646.